)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Applied Therapeutics
Applied Therapeutics (APLT) investor relations material
Applied Therapeutics has been acquired
Applied Therapeutics Q3 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2025 earnings summary13 Nov, 2025
Executive summary
Reported a net loss of $18.99 million for Q3 2025 and $62.1 million for the nine months ended September 30, 2025, with an accumulated deficit of $636.4 million.
Advanced regulatory discussions with the FDA for govorestat in CMT-SORD and Classic Galactosemia, with new meetings planned and prior Complete Response Letter and warning addressed.
Published and presented new positive clinical data on govorestat for PMM2-CDG, supporting further development.
Announced Board leadership transition with the resignation of the Executive Chairman for personal reasons.
Cash and cash equivalents were $11.9 million as of September 30, 2025, raising substantial doubt about the ability to continue as a going concern.
Financial highlights
Q3 2025 revenue: $1.0 million (vs. $0.1 million Q3 2024); nine months: $1.0 million (vs. $0.5 million prior year period).
Net loss per share: $(0.13) for Q3 2025 (vs. $(0.48) Q3 2024); $(0.43) for nine months (vs. $(1.09) prior year period).
R&D expenses for Q3 2025: $9.6 million (down from $14.8 million Q3 2024); nine months: $27.4 million (down from $37.0 million prior year).
G&A expenses for Q3 2025: $8.2 million (down from $15.0 million Q3 2024); nine months: $39.0 million (up from $34.7 million prior year, due to legal settlements and insurance recoveries).
Cash used in operations for nine months: $67.4 million (vs. $64.8 million prior year).
Outlook and guidance
Management expects continued significant operating losses and negative cash flows, with substantial additional funding required for ongoing operations and clinical development.
There is substantial doubt about the ability to continue as a going concern for 12 months beyond the filing date without additional capital.
The company is actively pursuing financing and business development opportunities but cannot assure success.
Plans to submit an additional Type C meeting request with the FDA to further discuss Phase 3 trial design for CMT-SORD.
Ongoing commitment to advancing govorestat development in multiple rare disease indications.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Applied Therapeutics
- Key votes include director election, auditor ratification, and a reverse stock split to maintain listing.APLT
Proxy Filing - Key votes include director election, auditor ratification, and a reverse stock split to maintain listing.APLTProxy Filing
- Key votes include director election, auditor ratification, and a proposed reverse stock split.APLTProxy Filing
- Net loss widened, cash declined, pipeline advanced, but major regulatory and funding risks remain.APLTQ2 2025
- Govorestat nears approval for two rare diseases, with launches expected in late 2024 and early 2025.APLT2024 Cantor Fitzgerald Global Healthcare Conference
- Q2 net income of $2.9M and $122.2M cash support late-stage regulatory progress.APLTQ2 2024
- Govorestat nears dual rare disease launches, backed by strong efficacy, safety, and market readiness.APLTUBS Global Healthcare Conference 2024
- Govorestat nears regulatory decisions as net loss widens and cash reserves strengthen.APLTQ3 2024
- Govorestat nears regulatory milestones for two rare diseases, with robust clinical and commercial readiness.APLTBaird's 2024 Global Healthcare Conference
Applied Therapeutics
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Applied Therapeutics Inc. is a clinical-stage biopharmaceutical company engaged in discovering and developing innovative drugs for conditions with significant unmet medical needs. The company focuses on novel drug candidates targeting validated molecular pathways in diseases such as Galactosemia, Diabetic Cardiomyopathy, Diabetic Peripheral Neuropathy, and other areas with high unmet medical needs. Among its pipeline, notable drug candidates include AT-001, an aldose reductase inhibitor for diabetic complications; AT-007 for rare diseases such as SORD Deficiency; and AT-003, designed for diabetic retinopathy. Additionally, Applied Therapeutics is exploring AT-104, a PI3K inhibitor for orphan hematological oncology, specifically T Cell Acute Lymphoblastic Leukaemia. Applied Therapeutics is headquartered in New York, NY, and its shares are listed on the NASDAQ.